We have recently reported that vatalanib, an orally active small molecule multi-tyrosine kinase inhibitor [1], can sensitize multidrug resistant (MDR) colon cancer cells to chemotherapy under hypoxia by inhibiting two MDR transporters ABCB1 and ABCG2 [2]. Here, ABCG2 is linked to malignant colon neoplasm.